Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours Β· Estimated delivery Aug 10 - Aug 15
It got through Phase 3 and into commercial use, at scale, and the real-world data keeps lining up with the trial data
On August 1, 2025, the JPML reported there are 2,190 cases pending in MDL -3094 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
PubMed laboratory research record [PMID: 23626603] PubMed record related to this compound for laboratory literature review
Common Side Effects Nausea Diarrhea Vomiting Constipation Stomach pain Decreased appetite Headache Serious Side Effects (Rare) Pancreatitis Gallbladder issues Kidney injury Serious allergic responses Vision alterations (in diabetic patients) Elevated heart rate A boxed warning highlights thyroid C-cell tumor risks from animal studies
Certain patients should not take GLP-1 medications
